The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. If you’re starting a weight loss journey, you might have ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...

The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The FDA released a Declaratory Order on December 19th re-evaluating and essentially re-instituting its previous position on the tirzepatide ...